Breast Cancer (BrCa) is a hormone-related malignancy. Current treatment plans target the hormone receptors, which also act as prognostic indicators. However, despite the advancement in treatment modalities, BrCa continues to be one of the most frequently diagnosed cancer in the world and the leading cause of cancer-related casualties in females. Accumulating evidence suggests that androgen signalling plays an important role in BrCa development and progression. With more than 60-80% of tumors expressing the Androgen Receptor (AR), the transcription factor has emerged as a potential prognostic marker and therapeutic target. We investigate the role of AR in the pathogenesis of BrCa using an integrated molecular approach. Our study aims to elucidate the role of AR as a probable therapeutic target in BrCa and help in understanding the genomic classification and characterization of BrCa amongst Indian women.


AwardAwarding agencyTimeline
Second prize in poster and third prize in the quiz competitionOncovision 2022November 2022
Young Investigator AwardKorean Society of Medical Oncology, South Korea September 2022
Internation Travel grantsSERB, AIIMS CSIR, & DBT, Govt of IndiaMarch-September 2022
MemberEuropean Society for Medical Oncology (ESMO)November 2022
Member-in-trainingAmerican Society of Clinical Oncology (ASCO)October 2020
Associate memberAmerican Association for Cancer Research (AACR)July 2020
MemberAmerican Society for Clinical Pathology (ASCP)September 2020
Junior Research Fellowship (CSIR-JRF) & (CSIR-NET) in Life sciencesCouncil of Scientific and Industrial Research (CSIR)June 2018
IELTS Academic overall band score 7.5 (L-8.5, R-8, W-6.5, S-7)British CouncilFebruary 2018
Graduate Aptitude Test in Engineering (GATE) Life SciencesIIT RoorkeeMarch 2017
Merit-cum-Means ScholarshipSouth Asian UniversityAug 2014 – May 2016